Research graph
References from Spatial and Interlesional Heterogeneity of FGFR2b Expression in Paired Primary and Metastatic Gastric and Gastroesophageal Junction Adenocarcinomas. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021
10.4143/crt.2024.253 · 2024 · External reference
Gastric cancer trends in Estonia 1995-2014 by age, subsite, morphology and stage
10.1080/0284186x.2018.1546058 · 2019 · External reference
Unresolved reference
External reference
Biomarker-driven approach to the treatment of metastatic gastric or gastroesophageal adenocarcinoma
10.6004/jnccn.2025.7036 · 2025 · External reference
Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells
10.2741/4609 · 2018 · External reference
Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
10.1093/annonc/mdx800 · 2018 · External reference
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
10.1080/19420862.2021.1981202 · 2021 · External reference
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial
10.1007/s10120-024-01466-w · 2024 · External reference
LBA10 Bemarituzumab plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer: FORTITUDE-101 phase III study results
10.1016/j.annonc.2025.09.092 · 2025 · External reference
Ocular safety evaluation of bemarituzumab in FGFR2b-overexpressing gastroesophageal adenocarcinoma: a 42-week follow-up study
10.1080/09273948.2025.2603496 · 2026 · External reference
Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial
2025 · External reference
Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
10.1038/s41598-021-84107-x · 2021 · External reference
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer
10.1007/s10120-025-01611-z · 2025 · External reference
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
10.1111/j.1365-2559.2011.04012.x · 2011 · External reference
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
10.1158/2159-8290.cd-20-1557 · 2021 · External reference
Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach
10.1016/j.modpat.2024.100589 · 2024 · External reference
HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
10.1093/ajcp/aqw206 · 2016 · External reference
PD-L1 testing in gastric cancer by the combined positive score of the 22C3 pharmDx and SP263 assay with clinically relevant cut-offs
10.4143/crt.2019.718 · 2020 · External reference
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer
10.1038/s41416-023-02382-z · 2023 · External reference
The expression of the tight junction protein and therapeutic target claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma
10.1038/s41598-025-12337-4 · 2025 · External reference
Spatial heterogeneity of FGFR2b in gastric cancer: a comparative analysis of primary tumors and peritoneal dissemination
10.1007/s00428-025-04233-z · 2026 · External reference
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
10.1016/j.esmoop.2025.105322 · 2025 · External reference
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
10.1038/modpathol.2016.96 · 2016 · External reference
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
10.1158/1078-0432.ccr-20-2085 · 2020 · External reference
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research
10.1002/ijc.30408 · 2016 · External reference
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single-institution study
2024 · External reference
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
10.1007/s10120-018-0891-1 · 2019 · External reference
Correlation and overlap between claudin 18.2 and FGFR2b overexpression: a tissue microarray study with 1,538 gastric carcinomas
10.5230/jgc.2025.25.e47 · 2025 · External reference
FGFR2b protein overexpression: an emerging biomarker in gastric and gastroesophageal junction adenocarcinoma
10.1016/j.ctrv.2025.102971 · 2025 · External reference
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
2025 · External reference
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
10.1038/s41571-026-01134-1 · 2026 · External reference
